



**RECOVERY
STARTS
HERE**

with a once-monthly treatment

ONCE-MONTHLY

Sublocade[®]
(buprenorphine extended-release)
injection for subcutaneous use Ⓜ
100mg•300mg

YOUR SUBLOCADE[®] START: A first step in long-term recovery

Every Step Is Worth Celebrating



Starting a new path to long-term recovery with once-monthly SUBLOCADE as part of your treatment program is something to celebrate.

Congratulations on taking this important step!

Why SUBLOCADE?



We know the idea of recovery can be stressful, but medication can help. SUBLOCADE is just one dose that lasts all month, with no real daily ups and downs. This may help you focus on counseling so you can work on your recovery goals.

INDICATION

Prescription SUBLOCADE, with counseling and psychosocial support, is for adults with moderate to severe opioid addiction who have started treatment with a dose of oral buprenorphine or are being treated with buprenorphine.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about SUBLOCADE?

- Because of serious risk of potential harm or death from self-injecting SUBLOCADE into a vein (intravenously), it is only available through a restricted program called the SUBLOCADE REMS Program.
- SUBLOCADE is not available in retail pharmacies.
- Your SUBLOCADE injection will only be given to you by a certified healthcare provider.
- SUBLOCADE contains a medicine called buprenorphine which is an opioid that can cause serious and life-threatening breathing problems, especially if you take or use certain other medicines or drugs.

See additional Important Safety Information throughout and the Medication Guide.

SUBLOCADE® is a proven once-monthly treatment with options to help fit your preferences

Treatment is different for everyone, but it is important for anyone on their recovery journey to get stable medication delivery.

SUBLOCADE offers 4 injection sites to choose from

- ✓ Abdomen
- ✓ Thigh
- ✓ Buttock
- ✓ Back of the upper arm

Injection sites should be rotated each month.



Start once-monthly SUBLOCADE, wherever you are in recovery

Already taking buprenorphine: You can transition directly to your first SUBLOCADE injection the **same day**

OR

Not already on buprenorphine: First, your doctor will give you a small test dose of buprenorphine under your tongue or inside your cheek to ensure you can tolerate the medicine and monitor you for an hour. If you respond well, you can receive your first SUBLOCADE injection the **same day**.



Your 2nd injection can be given as early as 1 week and up to 1 month after the 1st. Getting the 2nd injection after 1 week instead of a month later is designed to help you reach and maintain targeted levels of medicine earlier.

IMPORTANT SAFETY INFORMATION (CONT'D)

- Talk to your healthcare provider about naloxone, which is a medicine that is available to patients for emergency treatment of an opioid overdose. If naloxone is given, call 911 or get emergency medical help right away to treat overdose or accidental use of an opioid.
- **SUBLOCADE may cause serious and life-threatening breathing problems. Get emergency help right away if you:** feel faint, dizzy, confused, sleepy or uncoordinated, have blurred vision or slurred speech, are breathing slower than normal or cannot think well or clearly.
- **Do not take SUBLOCADE with certain medicines. Taking SUBLOCADE with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.**
- In an emergency, have family members tell emergency department staff that you are physically dependent on an opioid and are being treated with SUBLOCADE.

See additional Important Safety Information throughout and the [Medication Guide](#).

Your expectations matter

Here are some ways to prepare for your SUBLOCADE day:

- Start a list of questions for your provider ahead of time
- If injections make you anxious, think about ways to manage your stress
 - Bring a friend or loved one with you
 - Listen to music or meditate to help ease your appointment concerns



You might be wondering if the injection is painful. In a clinical study, pain decreased over the first 5 minutes at all 4 injection sites. **In another study, each monthly injection was less painful over time,** as measured by injections of SUBLOCADE in the abdomen. One of the most common side effects of SUBLOCADE is injection site pain.

Remember, SUBLOCADE gives you continuous medication delivery all month to help support your recovery. Sticking with your appointments can help you move closer to your recovery goals.

IMPORTANT SAFETY INFORMATION (CONT'D)

- You may have detectable levels of SUBLOCADE in your body for several months after stopping treatment with SUBLOCADE.

Who should not receive SUBLOCADE?

Do not receive SUBLOCADE if you are allergic to buprenorphine or any ingredient in the prefilled syringe (delivery system: a biodegradable 50:50 poly(DL-lactide-co-glycolide) polymer and a biocompatible solvent, N-methyl-2-pyrrolidone (NMP)).

Before starting SUBLOCADE, tell your healthcare provider about all of your medical conditions, including if you have: trouble breathing or lung problems, a curve in your spine that affects your breathing, Addison's disease, an enlarged prostate, problems urinating, liver, kidney, gallbladder or mental health problems, alcoholism, head injury or brain problem, adrenal or thyroid gland problems.

Tell your healthcare provider if you are pregnant or breastfeeding or plan to become pregnant or breastfeed:

- If you receive SUBLOCADE while pregnant, your baby may have symptoms of opioid withdrawal at birth that could be life-threatening if not recognized and treated. Talk to your healthcare provider if you are pregnant or plan to become pregnant.
- SUBLOCADE can pass into your breast milk and harm your baby. Talk to your healthcare provider about the best way to feed your baby during treatment with SUBLOCADE. Monitor your baby for increased drowsiness and breathing problems if you breastfeed during treatment with SUBLOCADE.

See additional Important Safety Information throughout and the Medication Guide.

ONCE-MONTHLY

Sublocade[®]

*(buprenorphine extended-release)
injection for subcutaneous use* Ⓢ
100mg•300mg

The most important thing about SUBLOCADE, for me, is that I don't actually think about it most of the time, which sounds like a small thing, but it is a really important thing.

MICHAEL
REAL SUBLOCADE PATIENT



Michael was paid by Indivior.
His story reflects his
personal experience
while taking SUBLOCADE.

IMPORTANT SAFETY INFORMATION (CONT'D)

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements before starting any new medicines and during or after stopping treatment with SUBLOCADE.

What should I avoid while being treated with SUBLOCADE?

- **Do not drive, operate heavy machinery, or perform any other dangerous activities until you know how SUBLOCADE affects you.** SUBLOCADE can make you sleepy, dizzy, or lightheaded, especially in the first few days after your injection and when your dose is changed.
- **Do not drink alcohol** or take prescription or over-the-counter medicines that contain alcohol during treatment with SUBLOCADE, because this can lead to loss of consciousness or even death.

What are the possible side effects of SUBLOCADE?

SUBLOCADE can cause serious side effects, including:

- **Trouble breathing.** Taking SUBLOCADE with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants can cause breathing problems that can lead to coma and death.
- **Sleepiness, dizziness, and problems with coordination.**
- **Physical dependence or abuse.**

See additional Important Safety Information throughout and the Medication Guide.

IMPORTANT SAFETY INFORMATION (CONT'D)

- **Liver problems.** Call your healthcare provider right away if you notice any of these symptoms: your skin or the white part of your eyes turns yellow (jaundice), dark or "tea-colored" urine, light colored stools (bowel movements), loss of appetite, pain, aching, or tenderness on the right side of your stomach area, or nausea. Your healthcare provider should do blood tests to check your liver before you start and during treatment with SUBLOCADE.
- **Allergic reaction.** You may have rash, hives, itching, swelling of your face, wheezing, light-headedness, feeling faint or loss of consciousness. Call your healthcare provider or get emergency help right away.
- **Opioid withdrawal.** Call your healthcare provider right away if you get any of these symptoms: shaking, sweating more than normal, feeling hot or cold more than normal, runny nose, watery eyes, goose bumps, diarrhea, vomiting, or muscle aches.
- **Decrease in blood pressure.** You may feel dizzy when you get up from sitting or lying down.

The most common side effects of SUBLOCADE include:

constipation, headache, nausea, injection site itching, vomiting, increase in liver enzymes, tiredness, or injection site pain. SUBLOCADE may affect fertility in males and females. Talk to your healthcare provider if this is a concern for you.

These are not all the possible side effects. Call your healthcare provider for medical advice about side effects.

To report a pregnancy or side effects associated with taking SUBLOCADE or any safety-related information, product complaint, request for medical information, or product query contact PatientSafetyNA@indivior.com or 1-877-782-6966. You are encouraged to report negative side effects of drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information, including Boxed Warning, and Medication Guide, or for more information about SUBLOCADE, visit www.sublocadehcp.com.

CLICK HERE TO
**LEARN MORE ABOUT
WHAT TO EXPECT
WITH SUBLOCADE**



© 2025 Indivior UK Limited | SUBLOCADE® and INDIVIOR® are registered trademarks of Indivior UK Limited or its affiliate companies. All rights reserved.

Intended Only for US Audiences.

P-BAG-US-01823 June 2025